Crescita Therapeutics (TSX:CTX) Cyclically Adjusted FCF per Share: C$-0.12 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
GF Value C$0.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Cyclically Adjusted FCF per Share?

Crescita Therapeutics TSX:CTX 20 Cyclically Adjusted FCF per Share is C$-0.12 as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Crescita Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was C$0.007. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is C$-0.12 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-13), Crescita Therapeutics's current stock price is C$0.79. Crescita Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was C$-0.12. Crescita Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Crescita Therapeutics  (TSX:CTX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Crescita Therapeutics Cyclically Adjusted FCF per Share Related Terms


Crescita Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Cyclically Adjusted FCF per Share Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.36 -0.20

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.27 -0.24 -0.20 -0.12

TSX:CTX vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Crescita Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.007/132.2623*132.2623
=0.007

Current CPI (Mar. 2026) = 132.2623.

Crescita Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.210 102.002 -0.272
201609 -0.249 101.765 -0.324
201612 -0.413 101.449 -0.538
201703 -0.255 102.634 -0.329
201706 -0.071 103.029 -0.091
201709 -0.091 103.345 -0.116
201712 -0.121 103.345 -0.155
201803 -0.068 105.004 -0.086
201806 -0.012 105.557 -0.015
201809 -0.042 105.636 -0.053
201812 0.028 105.399 0.035
201903 0.112 106.979 0.138
201906 0.051 107.690 0.063
201909 0.069 107.611 0.085
201912 0.000 107.769 0.000
202003 0.012 107.927 0.015
202006 0.002 108.401 0.002
202009 0.215 108.164 0.263
202012 0.028 108.559 0.034
202103 -0.010 110.298 -0.012
202106 -0.038 111.720 -0.045
202109 -0.013 112.905 -0.015
202112 -0.033 113.774 -0.038
202203 0.029 117.646 0.033
202206 -0.004 120.806 -0.004
202209 0.022 120.648 0.024
202212 -0.103 120.964 -0.113
202303 0.105 122.702 0.113
202306 0.004 124.203 0.004
202309 0.006 125.230 0.006
202312 -0.013 125.072 -0.014
202403 0.019 126.258 0.020
202406 0.028 127.522 0.029
202409 0.022 127.285 0.023
202412 0.072 127.364 0.075
202503 -0.030 129.181 -0.031
202506 -0.009 129.892 -0.009
202509 0.060 130.287 0.061
202512 0.020 130.366 0.020
202603 0.007 132.262 0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of C$-0.12 mean?
Crescita Therapeutics (TSX:CTX) has a Cyclically Adjusted FCF per Share of C$-0.12 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Cyclically Adjusted FCF per Share too high?
Crescita Therapeutics' current Cyclically Adjusted FCF per Share is C$-0.12. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Cyclically Adjusted FCF per Share compare to ZTS?
Crescita Therapeutics' Cyclically Adjusted FCF per Share of C$-0.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Cyclically Adjusted FCF per Share is C$-0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is C$-0.12. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Cyclically Adjusted FCF per Share is C$-0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:CTX:

  • Cyclically Adjusted FCF per Share: C$-0.12
  • GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price
C$0.68
GF Value